136 related articles for article (PubMed ID: 8849324)
1. Effect of v-rasH on sensitivity of NCI-H82 human small cell lung cancer cells to cisplatin, etoposide, and camptothecin.
Kaufmann SH; Kalemkerian GP; Jasti R; Mabry M
Biochem Pharmacol; 1995 Dec; 50(12):1987-93. PubMed ID: 8849324
[TBL] [Abstract][Full Text] [Related]
2. Induction of broad drug resistance in small cell lung cancer cells and its reversal by paclitaxel.
Su GM; Davey MW; Davey RA
Int J Cancer; 1998 May; 76(5):702-8. PubMed ID: 9610729
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Jain N; Lam YM; Pym J; Campling BG
Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of magainin analogues against human lung cancer cell lines.
Ohsaki Y; Gazdar AF; Chen HC; Johnson BE
Cancer Res; 1992 Jul; 52(13):3534-8. PubMed ID: 1319823
[TBL] [Abstract][Full Text] [Related]
5. Growth inhibition and induction of apoptosis by fenretinide in small-cell lung cancer cell lines.
Kalemkerian GP; Slusher R; Ramalingam S; Gadgeel S; Mabry M
J Natl Cancer Inst; 1995 Nov; 87(22):1674-80. PubMed ID: 7473815
[TBL] [Abstract][Full Text] [Related]
6. Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression.
Giaccone G; Gazdar AF; Beck H; Zunino F; Capranico G
Cancer Res; 1992 Apr; 52(7):1666-74. PubMed ID: 1312895
[TBL] [Abstract][Full Text] [Related]
7. In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.
Jensen PB; Holm B; Sorensen M; Christensen IJ; Sehested M
Br J Cancer; 1997; 75(6):869-77. PubMed ID: 9062409
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of novel orthotopic nude mouse models for human small-cell lung cancer.
Isobe T; Onn A; Morgensztern D; Jacoby JJ; Wu W; Shintani T; Itasaka S; Shibuya K; Koo PJ; O'Reilly MS; Herbst RS
J Thorac Oncol; 2013 Feb; 8(2):140-6. PubMed ID: 23328546
[TBL] [Abstract][Full Text] [Related]
9. Modulation of drug and radiation resistance in small cell lung cancer cells by paclitaxel.
Locke VL; Davey RA; Davey MW
Anticancer Drugs; 2003 Aug; 14(7):523-31. PubMed ID: 12960736
[TBL] [Abstract][Full Text] [Related]
10. p53 gene status modulates the chemosensitivity of non-small cell lung cancer cells.
Lai SL; Perng RP; Hwang J
J Biomed Sci; 2000; 7(1):64-70. PubMed ID: 10644891
[TBL] [Abstract][Full Text] [Related]
11. All-trans-retinoic acid alters myc gene expression and inhibits in vitro progression in small cell lung cancer.
Kalemkerian GP; Jasti RK; Celano P; Nelkin BD; Mabry M
Cell Growth Differ; 1994 Jan; 5(1):55-60. PubMed ID: 8123593
[TBL] [Abstract][Full Text] [Related]
12. Establishment of a 7-ethyl-10-hydroxy-camptothecin-resistant small cell lung cancer cell line.
Chikamori M; Takigawa N; Kiura K; Tabata M; Shibayama T; Segawa Y; Ueoka H; Ohnoshi T; Tanimoto M
Anticancer Res; 2004; 24(6):3911-6. PubMed ID: 15736431
[TBL] [Abstract][Full Text] [Related]
13. Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines.
Jensen PB; Christensen IJ; Sehested M; Hansen HH; Vindeløv L
Br J Cancer; 1993 Feb; 67(2):311-20. PubMed ID: 8094293
[TBL] [Abstract][Full Text] [Related]
14. Enhanced topoisomerase I activity and increased topoisomerase II alpha content in cisplatin-resistant cancer cell lines.
Minagawa Y; Kigawa J; Irie T; Kanamori Y; Itamochi H; Cheng X; Terakawa N
Jpn J Cancer Res; 1997 Dec; 88(12):1218-23. PubMed ID: 9473741
[TBL] [Abstract][Full Text] [Related]
15. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES
Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806
[TBL] [Abstract][Full Text] [Related]
16. Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line.
Kohara H; Tabata M; Kiura K; Ueoka H; Kawata K; Chikamori M; Aoe K; Chikamori K; Matsushita A; Harada M
Clin Cancer Res; 2002 Jan; 8(1):287-92. PubMed ID: 11801571
[TBL] [Abstract][Full Text] [Related]
17. Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines.
Janss AJ; Cnaan A; Zhao H; Shpilsky A; Levow C; Sutton L; Phillips PC
Anticancer Drugs; 1998 Aug; 9(7):641-52. PubMed ID: 9773809
[TBL] [Abstract][Full Text] [Related]
18. Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines.
Zangemeister-Wittke U; Schenker T; Luedke GH; Stahel RA
Br J Cancer; 1998 Oct; 78(8):1035-42. PubMed ID: 9792147
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a human small-cell lung cancer cell line resistant to a new water-soluble camptothecin derivative, DX-8951f.
Nomoto T; Nishio K; Ishida T; Mori M; Saijo N
Jpn J Cancer Res; 1998 Nov; 89(11):1179-86. PubMed ID: 9914787
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary.
Itamochi H; Kigawa J; Sultana H; Iba T; Akeshima R; Kamazawa S; Kanamori Y; Terakawa N
Jpn J Cancer Res; 2002 Jun; 93(6):723-8. PubMed ID: 12079522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]